Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model

Journal of Pharmaceutical Sciences

Volumn 97, Issue 9, 2008, Pages 4108-4117

  Katsube, Takayuki ^a,b   Yano, Yoshitaka ^a,c   Yamano, Yoshinori ^a   Munekage, Tadashi ^a   Kuroda, Naomi ^a   Takano, Mikihisa ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Mathematical model; Pharmacodynamics; Pharmacokinetic pharmacodynamic models; Pharmacokinetics; Simulations

Indexed keywords

DORIPENEM; MEROPENEM;

ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG DOSE REGIMEN; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PSEUDOMONAS AERUGINOSA;

EID: 53549129491     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21265     Document Type: Article

References (42)

1. Meibohm B, Derendorf H. 2002. Pharmacokinetic/ pharmacodynamic studies in drug product development. J Pharm Sci 91:18-31.
2. Sheiner LB, Steimer JL. 2000. Pharmacokinetic/ pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95.
3. Gerber AU, Feller-Segessenmann C. 1985. In-vivo assessment of in-vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother 15: 201-206.
4. Miwa H, Kimura Y, Jinushi Y, Fujimura T, Nishikawa T, Munekage T, Kuroda N, Yamano Y, Tsuji M, Okazaki K, Sato T, Matsuda H. 2005. Antipseudomonal activity of DRPM, a novel parenteral carbapenem antibiotic. Jpn J Chemother 53:80-91.
5. Zhanel GG, Karlowsky JA, Hoban DJ, Davidson RJ. 1991. Antimicrobial activity of subinhibitory concentration of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect. Chemotherapy 37:114-121.
6. Carret G, Flandrois JP, Lobry JR. 1991. Biphasic kinetics of bacterial killing by quinolones. J Antimicrob Chemother 27:319-327.
7. Hamano S, Tsuji A, Asano T, Tamai I, Nakashima E, Yamana T, Mitsuhashi S. 1984. Kinetic analysis and characterization of the bacterial regrowth after treatment of Escherichia coli with β-lactam antibiotics. J Pharm Sci 73:1422-1427.
8. Li RC, Nix DE, Schentag JJ. 1994. Pharmacodynamic modeling of bacterial kinetics: β-lactam antibiotics against Escherichia coli. J Pharm Sci 83: 970-975.
9. Mattie H. 1981. Kinetics of antimicrobial action. Rev Infect Dis 3:19-27.
10. Tsuji A, Hamano S, Asano T, Nakashima E, Yamana T, Mitsuhashi S. 1984. Microbial kinetics of β-lactam antibiotics against Escherichia coli. J Pharm Sci 73:1418-1422.
11. Yano Y, Oguma T, Nagata H, Sasaki S. 1998. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 87:1177-1183.
12. Robertson TB. 1923. The chemical basis of growth and senescence. Philadelphia and London: Lippincott.
13. Jusko WJ. 1973. A pharmacodynamic model for cell-cycle specific chemotherapeutic agents. J Pharmacokin Biopharm 1:175-200.
14. Zhi J, Nightingale CH, Quintiliani R. 1988. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokin Biopharm 16: 355-375.
15. de la Pena A, Grabe A, Rand KH, Rehak E, Gross J, Thyroff-Friesinger U, Muller M, Derendorf H. 2004. PK-PD modeling of the effect of cefaclor on four different bacterial strains. Int J Antimicrob Agents 23:218-225.
16. Delacher S, Derendorf H, Hollenstein U, Brunner M, Joukhadar C, Hofmann S, Georgopoulos A, Eichler HG, Muller M. 2000. A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target pharmacodynamics of antibiotics in humans. J Antimicrob Chemother 46:733-739.
17. Firsov AA, Lubenko IY, Vostrov SN, Kononenko OV, Zinner SH, Portnoy YA. 2000. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: Prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother 46:725-732.
18. Gustafsson I, Lowdin E, Odenholt I, Cars O. 2001. Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrob Agents Chemother 45:2436-2440.
19. Liu P, Rand KH, Obermann B, Derendorf H. 2005. Pharmacokinetic- Pharmacodynamic modelling of antibacterial activity of Cefpodoxime and Cefixime in in vitro kinetic models. Int J Antimicrob Agents 25:120-129.
20. Liu Q, Rand K, Derendorf H. 2004. Impact of tazobactam pharmacokinatics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents 23:494-497.
21. Nolting A, Dalla Costa T, Rand KH, Derendorf H. 1996. Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 13:91-96.
22. Goto Y, Hiramatsu K, Nasu M. 1999. Improved efficacy with nonsimultaneous administration of netilmicin and minocycline against methicillin-resistant Staphylococcus aureus in in vitro and in vivo models. Int J Antimicrob Agents 11: 39-46.
23. Kuroda N, Munekage T, Yamano Y. 2005. Bactericidal activity of DRPM using in vitro pharmacodynamic models. Jpn J Chemother 53:96-103.
24. Sasaki S, Nishimura K, Yoshida I, Munekage T, Imamura N. 1993. Study of an auto-simulation apparatus for evaluating bactericidal activity of antibiotics in human serum. Chemotherapy 41:1056-1063.
25. Barger A, Fuhst C, Wiedemann B. 2003. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 52:893-898.
26. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. 2006. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: Impact on the development of resistance. Drugs 66:1-14.
27. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents 19:261-268.
28. Drusano GL. 2003. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 36:S42-S50.
29. Tessier PR, Kim MK, Zhou W, Xuan D, Li C, Ye M, Nightingale CH, Nicolau DP. 2002. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 46:1425-1434.
30. Katsube T, Yamano Y, Yano Y. 2007. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J Pharm Sci (accepted)
31. Nakashima M, Oguma T. 2005. Phase I study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers. Jpn J Chemother 53: 104-123.
32. Nakashima M, Uematsu T, Kanamaru M, Ueno K. 1992. Clinical Phase I study of meropenem. Chemotherapy (Tokyo) 40:258-275.
33. Yamaoka K, Nakagawa T. 1983. A nonlinear least squares program on differential equations, MULTI(RUNGE), for microcomputers. J Pharmacobio-Dyn 6:595-606.
34. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.
35. Kneer J. 1993. Relevance of antibiotics tissue penetration in treating respiratory tract infections. Respiration 60:32-37.
36. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. 1991. Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning. Antimicrob Agents Chemother 35: 1947-1952.
37. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. 1991. Antibiotic tissue penetration and its relevance: Impacts of tissue penetration on infection response. Antimicrob Agents Chemother 35:1953-1959.
38. Liu P, Fuhrherr R, Webb AI, Obermann B, Derendorf H. 2005. Tissue penetration of Cefpodoxime into the skeletal muscle and lung in rats. Eur J Pharm Sci 25:439-444.
39. Araki H, Ogake N, Tsuneda R, Minami S, Watanabe Y, Tamai I, Tsuji A. 2002. Muscle distribution of antimicrobial agents after a single introavenous administration to rats. Drug Metabol Pharmacokinet 17:237-244.
40. Deguchi Y, Terasaki T, Yamada H, Tsuji A. 1992. An application of microdialysis to drug tissue distribution study: In vivo evidence for free-ligand hypothesis and tissue binding of β-lactam antoibiotics in interstitial fluids. J Pharmacobio-Dyn 15: 79-89.
41. Liu P, Muller M, Derendorf H. 2002. Rational dosing of antibiotics: The use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285-290.
42. Sumita Y, Nouda H, Tada E, Kohzuki T, Kato M, Okuda T, Fukasawa M. 1992. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals. Chemotherapy (Tokyo) 40:123-131.